---
title: "Top 5 HK Stock Gainers/Losers (>100B) (8.29)"
description: "WUXI BIO(02269) rose 6.96%, with a trading turnover 2.7 Billion HKD, and a year-to-date rose 89.1%. INNOVENT BIO(01801) rose 6.84%, with a trading turnover 2.5 Billion HKD, and a year-to-date rose 164"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/255150943.md"
published_at: "2025-08-29T08:30:51.000Z"
---

# Top 5 HK Stock Gainers/Losers (>100B) (8.29)

> WUXI BIO(02269) rose 6.96%, with a trading turnover 2.7 Billion HKD, and a year-to-date rose 89.1%. INNOVENT BIO(01801) rose 6.84%, with a trading turnover 2.5 Billion HKD, and a year-to-date rose 164.6%. SF HOLDING(06936) fell 11.62%, with a trading turnover 1.5 Billion HKD, and a year-to-date rose 20.2%. ZTE(00763) fell 9.27%, with a trading turnover 2.5 Billion HKD, and a year-to-date rose 47.9%.

Hang Seng Index has rose 0.32%, with a year-to-date rose 25%; Hang Seng TECH Index has rose 0.54%, with a year-to-date rose 27%.

WUXI BIO(02269) rose 6.96%, with a trading turnover 2.7 Billion HKD, and a year-to-date rose 89.1%.

INNOVENT BIO(01801) rose 6.84%, with a trading turnover 2.5 Billion HKD, and a year-to-date rose 164.6%.

SF HOLDING(06936) fell 11.62%, with a trading turnover 1.5 Billion HKD, and a year-to-date rose 20.2%.

ZTE(00763) fell 9.27%, with a trading turnover 2.5 Billion HKD, and a year-to-date rose 47.9%.

### Related Stocks

- [02269.HK - WUXI BIO](https://longbridge.com/en/quote/02269.HK.md)
- [01801.HK - INNOVENT BIO](https://longbridge.com/en/quote/01801.HK.md)
- [01093.HK - CSPC PHARMA](https://longbridge.com/en/quote/01093.HK.md)
- [02359.HK - WUXI APPTEC](https://longbridge.com/en/quote/02359.HK.md)
- [01177.HK - SINO BIOPHARM](https://longbridge.com/en/quote/01177.HK.md)
- [06936.HK - SF HOLDING](https://longbridge.com/en/quote/06936.HK.md)
- [00763.HK - ZTE](https://longbridge.com/en/quote/00763.HK.md)
- [01919.HK - COSCO SHIP HOLD](https://longbridge.com/en/quote/01919.HK.md)
- [06099.HK - CMSC](https://longbridge.com/en/quote/06099.HK.md)
- [02388.HK - BOC HONG KONG](https://longbridge.com/en/quote/02388.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts Innovent Biologics' Price Target to HK$114.64 From HK$105.08, Keeps at Buy | Nomura Adjusts Innovent Biologics' Price Target to HK$114.64 From HK$105.08, Keeps at Buy | [Link](https://longbridge.com/en/news/275882948.md) |
| China's Innovent clinches new Lilly deal for immunology, cancer drug development | China’s Innovent Biologics has secured a new deal with Eli Lilly for the development of immunology and oncology drugs, i | [Link](https://longbridge.com/en/news/275255059.md) |
| Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug | Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug | [Link](https://longbridge.com/en/news/275387692.md) |
| WuXi XDC Launches Cash Offer to Acquire All Remaining Shares of BioDlink | WuXi XDC Cayman Inc. has launched a voluntary conditional cash offer to acquire all remaining shares of BioDlink not alr | [Link](https://longbridge.com/en/news/275670240.md) |
| Wuxi Biologics FY Revenue RMB21,790 Million | WuXi Biologics (Cayman) :FY REVENUE RMB 21,790 MILLIONFY PROFIT EXPECTED TO INCREASE TO RMB5,733 MILLIONFY ADJUSTED NON- | [Link](https://longbridge.com/en/news/275534123.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.